Cargando…
Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival
Autores principales: | Tefferi, Ayalew, Singh, Amritpal, Gangat, Naseema, Al-Kali, Aref, Alkhateeb, Hassan, Shah, Mithun, Patnaik, Mrinal S., Elliott, Michelle A., Hogan, William J., Litzow, Mark R., Wolanskyj-Spinner, Alexandra, Hook, Christopher C., Mangaonkar, Abhishek, Viswanatha, David, Chen, Dong, Pardanani, Animesh, Begna, Kebede H., Ketterling, Rhett P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827171/ https://www.ncbi.nlm.nih.gov/pubmed/36073516 http://dx.doi.org/10.3324/haematol.2022.281495 |
Ejemplares similares
-
Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
por: Tefferi, Ayalew, et al.
Publicado: (2022) -
Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts
por: Mangaonkar, Abhishek A., et al.
Publicado: (2018) -
Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
por: Gangat, Naseema, et al.
Publicado: (2022) -
Mayo Clinic experience with 1123 adults with acute myeloid leukemia
por: Begna, Kebede H., et al.
Publicado: (2021) -
Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
por: Gangat, Naseema, et al.
Publicado: (2023)